A medication initially developed for a uncommon disorder might help prolong survival for individuals with a severe type of ovarian cancer, based on findings from a clinical study. This resistant form of ovarian cancer develops when the illness advances within six months after beginning chemotherapy that incorporates platinum compounds. Such treatments function by using platinum-based substances to halt cancer cell division. Typically, those diagnosed with this resistant ovarian cancer have a life expectancy of around one year, with few therapeutic choices available. Research featured in the Lancet examined information from 381 participants with this condition. They were given either standard therapy or relacorilant, an oral drug for managing Cushing’s syndrome, which stems from high cortisol levels. Following an average monitoring period of two years, the data indicated a 35% decrease in mortality risk for those on relacorilant versus standard care. On average, the relacorilant group survived four months longer than the comparison group. The investigators determined that these outcomes position relacorilant as a possible new benchmark for treating this resistant ovarian cancer. Another investigation with 643 patients showed that adding pembrolizumab to standard care resulted in an average survival of 17.7 months, compared to 14 months for standard care alone. Pembrolizumab is an immunotherapy that boosts the body’s defenses to target cancer cells. In the UK, ovarian cancer ranks as the sixth most frequent cancer in females, with approximately 7,600 new diagnoses annually. It represents about 4% of female cancer incidences, leading to roughly 3,900 fatalities each year. Both studies are in phase 3 and need additional evaluation prior to UK approval. Nonetheless, both relacorilant and pembrolizumab have received US Food and Drug Administration approval for treating resistant ovarian cancer.
